Bayer Aktiengesellschaft

(PINK:BAYRY)

Latest On Bayer Aktiengesellschaft (BAYRY):

Date/Time Type Description Signal Details
2023-05-18 13:16 ESTNewsBayer's kidney disease drug Kerendia gets Chinese regulator nod for expanded useN/A
2023-05-18 00:06 ESTNewsBayer Aktiengesellschaft 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-17 10:29 ESTNewsCancer-focused Boundless Bio closes $100M funding led by Bayer, RA CapitalN/A
2023-05-16 21:01 ESTNewsBayer Agriscience, Shades Of CortevaN/A
2023-05-16 06:40 ESTNewsBayer's stroke prevention drug asundexian gets 2nd FDA fast track statusN/A
2023-05-11 12:50 ESTNewsBayer AG Non-GAAP EPS of €2.95, revenue of €14.39B; targets outlook at lower end of guidanceN/A
2023-05-11 12:50 ESTNewsBayer Q1 sales dips as crop, pharma segments decline; glyphosate prices weigh on outlookN/A
2023-05-11 12:50 ESTNewsBayer AG (BAYZF) Q1 2023 Earnings Call TranscriptN/A
2023-05-02 05:56 ESTDividendA dividend of $0.63 has been announced on Mar 15, 2023. It will be paid May 15, 2023 with an ex-dividend date of May 2, 2023.Neutral
2023-05-02 04:00 ESTNewsBayer AG Still Dirt-Cheap, Investors Are Getting Its Pharma Business For 'Free'N/A
2023-04-28 13:12 ESTNewsBayer's Adempas for high blood pressure in lungs gets EMA nod for use in childrenN/A
2023-04-20 15:38 ESTNewsActivist Bluebell steps up pressure for Bayer breakup, supervisory board changes - reportN/A
2023-04-05 15:05 ESTNewsBayer to invest ~€60M in Ukrainian corn seed production siteN/A
2023-04-04 05:54 ESTNewsDelaware court finds in favor of Bayer in talc disagreement with MerckN/A
2023-03-24 02:59 ESTNewsBayer, Orion begin phase 3 trial of Nubeqa to expand prostate cancer indicationN/A
2023-03-21 12:31 ESTNewsBayer, Orion's Nubeqa gets approval in China for expanded use in prostate cancerN/A
2023-03-15 19:24 ESTNewsBayer, Microsoft launch cloud-based enterprise solutions for agri-food sectorN/A
2023-03-10 16:07 ESTNewsGene therapy developer AskBio appoints ex Amneal commercial chief as CEON/A
2023-03-09 09:09 ESTNewsBayer mulls $1B R&D investment in US pharma business in FY23 — reportN/A
2023-03-03 00:10 ESTNewsBayer: Improving Business And Still UndervaluedN/A
2023-03-01 18:53 ESTNewsBayer files for approval of high dose Eylea in JapanN/A
2023-03-01 18:53 ESTNewsBayer: Disappointing Outlook Doesn't Change The Deep Value ThesisN/A
2023-03-01 03:36 ESTNewsBayer AG (BAYZF) Q4 2022 Earnings Call TranscriptN/A
2023-02-28 12:20 ESTNewsBayer's Q4 sales grow on back of crop products, pharma declines; FY23 EPS to see impactN/A
2023-02-28 12:20 ESTNewsBayer Aktiengesellschaft 2022 Q4 - Results - Earnings Call PresentationN/A
2023-02-27 07:55 ESTNewsOrion wins approval for darolutamide in Japan for metastatic prostate cancerN/A
2023-02-26 18:48 ESTNewsBayer adds activist Jeff Ubben to sustainability council - reportN/A
2023-02-22 19:43 ESTNewsBayer AG: Potential To Double Over 12-18 MonthsN/A
2023-02-10 07:01 ESTNewsBayer's kidney disease drug Kerendia gets approval for expanded use in EUN/A
2023-02-09 18:00 ESTNewsRegeneron wins FDA nod for Eylea to prevent infant blindnessN/A
2023-02-08 14:57 ESTNewsNovartis, Bayer commit financial aid to quake hit Turkey, Syria as rescue operations continueN/A
2023-02-08 14:57 ESTNewsBayer gains as former Roche pharma head becomes new CEON/A
2023-02-07 12:44 ESTNewsBayer files for approval of high/extended dosing regimens of Eylea in EUN/A
2023-02-02 11:36 ESTNewsBayer, Kimitec team up to develop biological crop protection solutionsN/A
2023-01-31 09:09 ESTNewsBayer to distribute M2i's pheromone-based biological crop protection productsN/A
2023-01-27 15:21 ESTNewsEMA panel backs expanded approval of Bayer's prostate cancer drug NubeqaN/A
2023-01-24 09:10 ESTNewsBayer's contrast agent Ultravist gets approval in EU for use in breast cancer detectionN/A
2023-01-20 11:59 ESTNewsBayer, Oerth Bio team up to develop sustainable crop protection productsN/A
2023-01-18 13:12 ESTNewsBayer acquires AI imaging company Blackford Analysis to bolster radiology portfolioN/A
2023-01-18 13:12 ESTNewsBayer: A Strong Buy NowN/A
2023-01-12 16:14 ESTNewsBayer, Google Cloud team up for early drug discoveryN/A
2023-01-10 16:14 ESTNewsBayer gains as activist Jeff Ubben pushes for outside CEO (update)N/A
2023-01-10 16:14 ESTNewsBayer extends gains amid report of activist investor push for breakupN/A
2023-01-09 22:27 ESTNewsBayer gets a boost as Ubben's hedge fund buys 0.8% stakeN/A
2022-12-18 17:08 ESTNewsBayer AG: Turnaround Value StockN/A
2022-12-16 12:51 ESTNewsBayer's kidney disease drug Kerendia gets EMA committee backing for expanded useN/A
2022-11-11 20:16 ESTNewsEMA panel backs approval of Regeneron, Bayer's Eylea for eye disorder in infantsN/A
2022-11-09 15:31 ESTNewsBayer: Q3 Earnings Reveal Bullish Narrative In The MakingN/A
2022-11-08 21:59 ESTNewsBayer's Q3 sales grow on back of Herbicides, while Xarelto slumps; confirms FY22 outlookN/A
2022-11-08 21:58 ESTNewsBayer Aktiengesellschaft 2022 Q3 - Results - Earnings Call PresentationN/A

About Bayer Aktiengesellschaft (BAYRY):

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

BAYRY Quotes by TradingView

See Advanced Chart

General

  • Name Bayer Aktiengesellschaft
  • Symbol BAYRY
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-General
  • Full Time Employees 95,955
  • Last Split Factor4:1
  • Last Split Date2017-09-20
  • Fiscal Year EndDecember
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.bayer.com
View More

Valuation

  • Trailing PE 8.62
  • Forward PE 9.34
  • Price/Sales (Trailing 12 Mt.) 1.26
  • Price/Book (Most Recent Quarter) 1.72
  • Enterprise Value Revenue 2.34
  • Enterprise Value EBITDA 10.06
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin -25%
  • Return on Assets 4%
  • Return on Equity -40%
  • Earnings Per Share $1.84
  • Revenue Per Share $0
  • Gross Profit 25.67 billion
  • Quarterly Earnings Growth -7%
View More

Highlights

  • Market Capitalization 61.8 billion
  • PEG Ratio 21.72
  • Analyst Target Price $17.2
  • Book Value Per Share $14.93
View More

Share Statistics

  • Shares Outstanding 3.93 billion
  • Shares Float 3.93 billion
  • % Held by Insiders <1%
  • % Held by Institutions 0.18%
  • Shares Short Prior Month 611188
View More

Technicals

  • Beta 1.33
  • 52 Week High $20.77
  • 52 Week Low $11.65
  • 50 Day Moving Average 16.01
  • 200 Day Moving Average 14.97
View More

Dividends

  • Forward Annual Dividend Rate $0.76
  • Forward Annual Dividend Yield 4.84%
  • Payout Ratio 42%
  • Dividend Date 2020-05-14
  • ExDividend Date 2020-04-29
  • Dividend Per Share $3.26
  • Dividend Yield 0%
View More

Bayer Aktiengesellschaft (BAYRY) Dividend Calendar:

BAYRY's last dividend payment was made to shareholders on May 14, 2020.
Bayer Aktiengesellschaft pays out 42% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Bayer Aktiengesellschaft (BAYRY) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A$0.40$0.386.16%
2020-09-302020-11-03$N/A$0.24$0.41-43.11%
2020-06-302020-08-04$N/A$0.47$0.447%
2020-03-312020-04-27$N/A$0.72$0.5434.34%
2019-12-312020-02-27$12.05 billion$0.35$0.342.87%
2019-09-302019-10-30$10.71 billion$0.32$0.299.44%
2019-06-302019-07-30$879.76 billion$0.45$0.46-2.63%
2019-03-312019-04-25$14.59 billion$0.71$0.4751.13%
2018-12-312019-02-27$12.69 billion$0.31$0.2622.54%
2018-09-302018-11-13$11.47 billion$0.34$0.49-30.8%
2018-06-302018-09-05$11.03 billion$0.45$0.48-6.43%
2018-03-312018-05-03$11.26 billion$0.68
2017-12-312018-02-28$10.89 billion$0.05
2017-09-302017-10-26$10.22 billion$1.29
2017-06-302017-07-27$10.63 billion$0.38
2017-03-312017-04-27$10.36 billion$0.63
2016-12-312017-02-22$7.52 billion$0.31$0.34-8.92%
2016-09-302016-10-26$9.65 billion$0.47$0.463.65%
2016-06-302016-07-27$6.2 billion$0.46
2016-03-312016-04-26$13.5 billion$0.67$0.627.25%
2015-12-312016-02-25$11.2 billion$0.30$0.31-5.28%
2015-09-302015-10-29$12.3 billion$0.47$0.4114.63%
2015-06-302015-07-29$13.88 billion$0.38
2015-03-312015-04-30$12.67 billion$0.44
2014-12-312015-02-26$11.45 billion$0.08
2014-09-302014-10-30$10.4 billion$0.32
2014-06-302014-07-30$13.91 billion$0.39
2014-03-312014-04-28$14.26 billion$0.58
2013-12-312014-02-28$14.36 billion$0.19
2013-09-302013-10-31$14.13 billion$0.29
2013-06-302013-07-31$13.68 billion$0.33
2013-03-312013-04-25$13.16 billion$0.45
2012-12-312013-02-28$13.99 billion$0.15
2012-09-302012-10-30$12.8 billion$0.20
2012-06-302012-07-31$12.21 billion$0.19
2012-03-312012-04-26$13.41 billion$0.41
2011-12-312012-02-28$10.62 billion$0.16
2011-09-302011-10-27$9.66 billion$0.27
2011-06-302011-07-28$13.76 billion$0.32
2011-03-312011-04-28$13.35 billion$0.28
2010-12-312011-02-28$11.09 billion-$0.08
2010-09-302010-10-28$13.96 billion$0.11
2010-06-302010-07-29$10.25 billion$0.20
2010-03-312010-04-29$11.25 billion$0.28
2009-09-302009-10-27$11.78 billion$0.11
2009-06-302009-07-29$11.83 billion$0.23
2009-03-312009-04-29$10.47 billion$0.18
2008-12-312009-03-03$10.62 billion$0.08
2008-09-302008-10-29$8.35 billion$0.13
2008-06-302008-07-30$13.35 billion$0.27
2008-03-312008-04-24$13.49 billion$0.34
2007-12-312008-02-28$11.84 billion$0.04
2007-09-302007-11-06$12.58 billion$0.49
2007-06-302007-08-07$11.54 billion$0.28
2007-03-312007-05-08$11.34 billion$1.11
2006-12-312007-03-15$11.96 billion$0.14
2006-09-302006-11-27$9.42 billion$0.13
2006-06-302006-08-01$9.27 billion$0.18
2006-03-312006-04-27$8.5 billion$0.24
2005-12-312006-03-06$5.24 billion$0.02
2005-09-302005-11-09$8.16 billion$0.20
2005-06-302005-08-10$7.99 billion$0.17
2005-03-312005-05-10$8.78 billion$0.29
2002-06-302002-06-30$7.96 billion$0.09
2002-03-312002-03-31$6.11 billion$0.15

Bayer Aktiengesellschaft (BAYRY) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Bayer Aktiengesellschaft (BAYRY) Chart:

Bayer Aktiengesellschaft (BAYRY) News:

Below you will find a list of latest news for Bayer Aktiengesellschaft (BAYRY) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bayer Aktiengesellschaft (BAYRY) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Bayer Aktiengesellschaft (BAYRY) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2018-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1144145/000002990518000006/0000029905-18-000006-index.htm
2016-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1144145/000089924316031911/0000899243-16-031911-index.htm
2016-05-23SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916122666/0001104659-16-122666-index.htm
2016-05-24SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916122970/0001104659-16-122970-index.htm
2016-05-25SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916123079/0001104659-16-123079-index.htm
2016-05-25SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916123351/0001104659-16-123351-index.htm
2016-05-26SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916123717/0001104659-16-123717-index.htm
2016-05-31SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916124111/0001104659-16-124111-index.htm
2016-05-31SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916124488/0001104659-16-124488-index.htm
2016-06-01SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916124870/0001104659-16-124870-index.htm
2016-06-02SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916125135/0001104659-16-125135-index.htm
2016-06-03SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916125439/0001104659-16-125439-index.htm
2016-06-06SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916125683/0001104659-16-125683-index.htm
2016-06-09SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916126422/0001104659-16-126422-index.htm
2016-06-10SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916126623/0001104659-16-126623-index.htm
2016-06-13SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916126873/0001104659-16-126873-index.htm
2016-06-15SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916127378/0001104659-16-127378-index.htm
2016-06-21SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916128617/0001104659-16-128617-index.htm
2016-06-28SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916129778/0001104659-16-129778-index.htm
2016-07-05SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916130982/0001104659-16-130982-index.htm
2016-07-14SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916132661/0001104659-16-132661-index.htm
2016-07-27SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916134588/0001104659-16-134588-index.htm
2016-09-06SC TO-CWritten communication relating to an issuer or third partyhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916143185/0001104659-16-143185-index.htm
2016-09-14DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916144533/0001104659-16-144533-index.htm
2016-09-14DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916144642/0001104659-16-144642-index.htm
2016-09-16DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916145111/0001104659-16-145111-index.htm
2016-09-20DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916145541/0001104659-16-145541-index.htm
2016-09-20DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916145707/0001104659-16-145707-index.htm
2016-09-21DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916145901/0001104659-16-145901-index.htm
2016-10-11DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916149617/0001104659-16-149617-index.htm
2016-10-12DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916149809/0001104659-16-149809-index.htm
2016-10-13DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916150093/0001104659-16-150093-index.htm
2016-10-17DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916150516/0001104659-16-150516-index.htm
2016-10-28DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916152889/0001104659-16-152889-index.htm
2016-10-31DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916153321/0001104659-16-153321-index.htm
2016-11-09DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916155876/0001104659-16-155876-index.htm
2016-11-10DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916156280/0001104659-16-156280-index.htm
2016-11-15DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916157318/0001104659-16-157318-index.htm
2016-11-16DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916157613/0001104659-16-157613-index.htm
2016-11-25DFAN14AAdditional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1144145/000110465916159086/0001104659-16-159086-index.htm

Bayer Aktiengesellschaft (BAYRY) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bayer Aktiengesellschaft (BAYRY). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: < 1%
Institutional Ownership: 18%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-01-05AKTIENGESELLSCHAFT BAYER10% Share HolderBuy527,472.0022.7511,999,988.005,632,802.00https://www.sec.gov/Archives/edgar/data/1144145/000002990518000006/0000029905-18-000006-index.htm